Tempest Therapeutics, Inc. (TPST) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TPST Revenue Growth
TPST Revenue Analysis (2013–2024)
As of May 8, 2026, Tempest Therapeutics, Inc. (TPST) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, TPST's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $9.7 million in 2014.
When compared to Healthcare sector peers including AGEN (+10.4% YoY), AGIO (+78.3% YoY), and RCUS (+67.4% YoY). Compare TPST vs AGEN →
TPST Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TPSTCurrent | $0 | - | - | - | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% |
TPST Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-389,000 | - | $-42,026,000 | - |
| 2023 | $0 | - | $0 | - | $-29,157,000 | - |
| 2022 | $0 | - | $0 | - | $-34,640,000 | - |
| 2021 | $0 | - | $0 | - | $-26,986,000 | - |
| 2020 | $0 | - | $-815,000 | - | $-19,298,000 | - |
| 2019 | $0 | - | $-1,052,000 | - | $-45,399,000 | - |
| 2018 | $0 | -100.0% | $-32,000 | - | $-23,116,000 | - |
| 2017 | $295K | -54.8% | $267K | 90.5% | $-20,482,000 | -6943.1% |
| 2016 | $653K | +135.7% | $-4,748,000 | -727.1% | $-81,012,000 | -12406.1% |
| 2015 | $277K | -97.2% | $-1,972,000 | -711.9% | $-71,999,000 | -25992.4% |
See TPST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TPST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TPST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTPST — Frequently Asked Questions
Quick answers to the most common questions about buying TPST stock.
Is TPST's revenue growth accelerating or slowing?
TPST TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is TPST's long-term revenue growth rate?
Tempest Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is TPST's revenue distributed by segment?
TPST reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.